{"id":"bcd-055","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"}]},"_chembl":{"chemblId":"CHEMBL5943759","moleculeType":null,"molecularWeight":"369.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BCD-055 is a fully human monoclonal antibody targeting programmed death ligand 1 (PD-L1) on tumor cells and immune cells. By blocking the PD-L1/PD-1 axis, the drug prevents tumor cells from suppressing T-cell activity, thereby reinvigorating cytotoxic T-lymphocyte responses against cancer. This mechanism is similar to other checkpoint inhibitors and is designed to enhance durable anti-tumor immunity.","oneSentence":"BCD-055 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:17.857Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (under investigation)"}]},"trialDetails":[{"nctId":"NCT02762838","phase":"PHASE3","title":"Comparative Clinical Trial of Efficacy and Safety of BCD-055 and Remicade® in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Biocad","startDate":"2016-01","conditions":"Rheumatoid Arthritis","enrollment":426},{"nctId":"NCT02762812","phase":"PHASE3","title":"Comparative Clinical Trial to Evaluate Efficacy and Safety of BCD-055 and Remicade® in Patients With Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Biocad","startDate":"2016-01","conditions":"Ankylosing Spondylitis","enrollment":199},{"nctId":"NCT02359903","phase":"PHASE1","title":"Comparative Evaluation of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Biocad","startDate":"2015-02","conditions":"Ankylosing Spondylitis","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["infliximab"],"phase":"phase_3","status":"active","brandName":"BCD-055","genericName":"BCD-055","companyName":"Biocad","companyId":"biocad","modality":"Biologic","firstApprovalDate":"","aiSummary":"BCD-055 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}